IPO registrations (S-1, F-1) · Registrants
SciSparc Ltd.
- SEC CIK
- 1611746 · filings on EDGAR ↗
- Former names
- SciSparc Ltd./ADR (2021–2021); Therapix Biosciences Ltd. (2014–2021)
- Registration
- Form F-1, first filed 2016-11-04, last 2024-08-28; 6 initial registrations, 16 amendments
- Outcome
- Final prospectus filed 2017-03-22; declared effective 2017-03-21; withdrawal requested 2025-11-04
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- L3
- Business address
- 20 RAUL WALLENBERG STREET, TOWER A, Tel Aviv, L3 6971916
- Ticker
- SPRC (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- SciSparc Ltd. on the corporate pages
Offering terms
- Proposed price range
- $5.00–$7.00 per ADS (F-1/A filed 2017-03-20)
- Final price
- $6.00 per ADS, within the range (424B4 filed 2017-03-22, an initial public offering)
- Shares sold
- 2,000,000
- Gross proceeds
- $12,000,000 before underwriting discounts and any over-allotment option
- Listing
- OTC under the symbol THXBY
- Lead underwriters
- Laidlaw & Company
- Syndicate
- Number of ADSs Laidlaw & Company (UK) Ltd (2,000,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: SciSparc Ltd. EXACT (CIK (EXACT))
- SEC filer: SciSparc Ltd. EXACT (CIK (EXACT))
Filings 50
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2016-11-04 | F-1 | F-1 (foreign registration) | Therapix Biosciences Ltd. | 0001213900-16-017994 ↗ |
| 2016-11-23 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-16-018920 ↗ |
| 2016-12-06 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-16-019159 ↗ |
| 2016-12-14 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-16-019394 ↗ |
| 2016-12-15 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-16-019444 ↗ |
| 2016-12-20 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-16-019546 ↗ |
| 2017-03-03 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-17-001948 ↗ |
| 2017-03-15 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-17-002306 ↗ |
| 2017-03-20 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-17-002573 ↗ |
| 2017-03-21 | EFFECT | EFFECT (declared effective) | Therapix Biosciences Ltd. | 9999999995-17-000606 ↗ |
| 2017-03-22 | 424B4 | 424B4 (final prospectus) | Therapix Biosciences Ltd. | 0001213900-17-002699 ↗ |
| 2018-07-20 | EFFECT | EFFECT (declared effective) | Therapix Biosciences Ltd. | 9999999995-18-001847 ↗ |
| 2019-09-05 | EFFECT | EFFECT (declared effective) | Therapix Biosciences Ltd. | 9999999995-19-002024 ↗ |
| 2020-01-31 | F-1 | F-1 (foreign registration) | Therapix Biosciences Ltd. | 0001213900-20-002182 ↗ |
| 2020-03-19 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-20-006836 ↗ |
| 2020-03-26 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-20-007401 ↗ |
| 2020-03-30 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-20-007879 ↗ |
| 2020-03-31 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-20-008164 ↗ |
| 2020-03-31 | EFFECT | EFFECT (declared effective) | Therapix Biosciences Ltd. | 9999999995-20-000648 ↗ |
| 2020-04-02 | 424B4 | 424B4 (final prospectus) | Therapix Biosciences Ltd. | 0001213900-20-008471 ↗ |
| 2020-09-08 | F-1 | F-1 (foreign registration) | Therapix Biosciences Ltd. | 0001213900-20-025655 ↗ |
| 2020-10-09 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-20-030687 ↗ |
| 2020-10-21 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-20-032425 ↗ |
| 2020-11-04 | F-1/A | F-1/A (amendment) | Therapix Biosciences Ltd. | 0001213900-20-034984 ↗ |
| 2020-11-18 | EFFECT | EFFECT (declared effective) | Therapix Biosciences Ltd. | 9999999995-20-003213 ↗ |
| 2020-11-19 | F-1MEF | F-1MEF (added securities) | Therapix Biosciences Ltd. | 0001213900-20-038140 ↗ |
| 2020-11-20 | 424B4 | 424B4 (final prospectus) | Therapix Biosciences Ltd. | 0001213900-20-038492 ↗ |
| 2021-04-01 | EFFECT | EFFECT (declared effective) | SciSparc Ltd./ADR | 9999999995-21-001247 ↗ |
| 2021-04-01 | EFFECT | EFFECT (declared effective) | SciSparc Ltd./ADR | 9999999995-21-001249 ↗ |
| 2021-04-21 | F-1 | F-1 (foreign registration) | SciSparc Ltd./ADR | 0001213900-21-022427 ↗ |
| 2021-04-28 | F-1/A | F-1/A (amendment) | SciSparc Ltd./ADR | 0001213900-21-023287 ↗ |
| 2021-04-29 | EFFECT | EFFECT (declared effective) | SciSparc Ltd./ADR | 9999999995-21-001635 ↗ |
| 2021-08-30 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-21-003350 ↗ |
| 2021-08-30 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-21-003351 ↗ |
| 2021-10-19 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-21-003931 ↗ |
| 2022-05-03 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-22-001269 ↗ |
| 2022-07-20 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-22-002114 ↗ |
| 2023-02-23 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-23-000465 ↗ |
| 2023-03-15 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-23-000583 ↗ |
| 2023-11-22 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-23-003419 ↗ |
| 2024-02-27 | F-1 | F-1 (foreign registration) | SciSparc Ltd. | 0001213900-24-017526 ↗ |
| 2024-03-06 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-24-000611 ↗ |
| 2024-06-24 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-24-001925 ↗ |
| 2024-08-28 | F-1 | F-1 (foreign registration) | SciSparc Ltd. | 0001213900-24-073359 ↗ |
| 2024-09-05 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-24-002734 ↗ |
| 2025-07-21 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-25-002296 ↗ |
| 2025-07-30 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-25-002403 ↗ |
| 2025-11-04 | RW | RW (withdrawal request) | SciSparc Ltd. | 0001213900-25-105619 ↗ |
| 2026-01-12 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-26-000145 ↗ |
| 2026-02-12 | EFFECT | EFFECT (declared effective) | SciSparc Ltd. | 9999999995-26-000555 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-03-20 | F-1/A | registration statement | $5.00–$7.00 | $6.00 | 2,000,000 | $12,000,000 | OTC THXBY | 1 | primary document; range, price sentence, shares headline, proceeds computed, cover names 1 | document ↗ |
| 2017-03-22 | 424B4 | final prospectus | $6.00 | 2,000,000 | $12,000,000 | OTC THXBY | 2 | primary document; price sentence, shares headline, proceeds table, underwriting table 1, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Adler Oz | Officer | CEO and CFO | 2 | 2026 | |
| Revach Moshe | Director | 2 | 2026 | ||
| Shay Amnon Ben | Director | 2 | 2026 | ||
| Shrem Itschak | Director | 3 | 2026 | ||
| Sidi Liat | Director | 2 | 2026 | ||
| Vider Lior | Director | 2 | 2026 | ||
| Weiss Amitay | Director | 2 | 2026 | ||
| Zuloff-Shani Adi | Officer | Chief Technology Officer | 2 | 2026 | |
| DAYAN ALON | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-03-03 | SciSparc Ltd. | Pharmaceuticals | $4,200,000 | $4,200,000 | 4 | 1 |
| 2023-10-19 | SciSparc Ltd. | Pharmaceuticals | $5,026,000 | $5,026,000 | 1 | 1 |
| 2022-06-08 | SciSparc Ltd. | Pharmaceuticals | $10,000,002 | $10,000,002 | 1 | 1 |
| 2021-03-09 | SciSparc Ltd./ADR | Pharmaceuticals | $3,873,031 | $0 | 18 | 1 |
| 2019-04-09 | Therapix Biosciences Ltd. | Other Health Care | $2,249,986 | $2,249,986 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | SciSparc Ltd. | Form D private offerings | CIK (EXACT) | |
| SEC filer | SciSparc Ltd. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, L3 first:
- CANNAPOWDER, INC. L3
- Rosetta Genomics Ltd. L3
- BIOCANCELL THERAPEUTICS INC. L3
- Can-Fite BioPharma Ltd. L3
- RedHill Biopharma Ltd. L3
- KAMADA LTD L3
- MAPI - PHARMA LTD L3
- NeuroDerm Ltd. L3
- Advanced Inhalation Therapies (AIT) Ltd. L3
- Silenseed Ltd. L3
In other datasets, the same topic (Health) in L3:
- Form D issuer: Agada Medical Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health